glp 1 non alcoholic fatty liver Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Disease: A Clinical Perspective Therapeutic Mechanisms and Clinical Effects

Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care

The results showed that the terminal body weight of ob/ob-GAN NASH mice increased to 70.01 1.11 g, equivalent to a gain of 9.25 1.09% relative to the initial weight

According to the American Diabetes Association (ADA), GLP-1 therapy is mainly used for managing type 2 diabetes by aiding in controlling blood sugar levels through stimulating insulin release and decreasing glucose production in the liver while also delaying the digestion process in the stomach

Horneff said more research is needed to understand why GLP-1 drugs might affect bone health

To fully realize the translational potential of GLP-1R agonists, future efforts must address gaps in implementation and integrate real-world evidence into clinical decision-making

Personalized treatment approaches matter